Moderna Is Maintained at Equal-Weight by Morgan Stanley
Moderna Analyst Ratings
Major rating|Morgan Stanley: Downgrades Moderna's Target Price to $38, maintains a "Neutral" rating.
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $38
J.P. Morgan Downgrades Moderna(MRNA.US) to Sell Rating
BofA Securities Maintains Moderna(MRNA.US) With Sell Rating, Maintains Target Price $41
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $55
UBS Group has lowered the Target Price for Moderna to 96 dollars.
Moderna Analyst Ratings
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $55
UBS Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $96
Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
Moderna Analyst Ratings
Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
BofA Securities Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $41
Moderna Analyst Ratings
B of A Securities Reinstates Underperform on Moderna, Announces $41 Price Target
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $69
Moderna Analyst Ratings
JPMorgan Adjusts Price Target on Moderna to $45 From $59, Maintains Underweight Rating